News Quantified

MESO – mesoblast limited - american depositary shares (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Mesoblast Acquires Chimeric Antigen Receptor (CAR) Platform Technology for Precision-Enhanced Cell Products

ASX April 2026 Stocks Estimated To Be Trading Below Fair Value [Yahoo! Finance]

Mesoblast Receives IND Clearance From FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy - CORRECTION

Mesoblast R&D Day: Ryonsel Gains Traction, Back Pain Phase III Nears Finish, New Shots on Goal [Yahoo! Finance]

Mesoblast R&D Day Features Significant Commercial Progress & Platform Innovation

Form 4 MESOBLAST LTD For: Apr 09 Filed by: George Gregory

Form 4 MESOBLAST LTD For: Apr 09 Filed by: George Gregory

Form 3 MESOBLAST LTD For: Mar 18 Filed by: BURNS WILLIAM MURRAY

Form 3 MESOBLAST LTD For: Mar 18 Filed by: Itescu Silviu

Form 3 MESOBLAST LTD For: Mar 18 Filed by: Itescu Silviu

Top News Gainers

4/24 83% Survival in COVID-19 Patients with Moderate/Severe Acute Respiratory Distress Syndrome Treated in New York with Mesoblast’s Cell Therapy Remestemcel-L 91.9%

4/6 FDA CLEARS INVESTIGATIONAL NEW DRUG APPLICATION FOR MESOBLAST TO USE REMESTEMCEL-L IN PATIENTS WITH ACUTE RESPIRATORY DISTRESS SYNDROME CAUSED BY COVID-19 27.0%

9/9 Grünenthal and Mesoblast Enter Strategic Partnership for Europe and Latin America to Develop and Commercialise Innovative Cell Therapy for the Treatment of Chronic Low Back Pain 20.9%

4/8 MESOBLAST PARTNERS WITH THE CARDIOTHORACIC SURGICAL TRIALS NETWORK ESTABLISHED BY THE U.S. NATIONAL INSTITUTES OF HEALTH’S NATIONAL HEART, LUNG AND BLOOD INSTITUTE TO CONDUCT RANDOMIZED CONTROLLED TRIAL OF REMESTEMCEL-L FOR PATIENTS WITH ACUTE RESPIRATORY 11.4%

12/17 Mesoblast’s Phase 3 Trial of Revascor in Advanced Chronic Heart Failure Surpasses the Number of Primary Endpoint Events for Trial Completion 10.4%

4/29 Mesoblast limited (NASDAQ: MESO) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $13.00 price target on the stock. 8.7%

3/30 CLINICAL OUTCOMES OF MESOBLAST’S CELL THERAPY IN END-STAGE ISCHEMIC HEART FAILURE PRESENTED AT AMERICAN COLLEGE OF CARDIOLOGY VIRTUAL SCIENTIFIC SESSIONS 8.5%

9/10 Mesoblast limited (NASDAQ: MESO) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 7.7%

6/24 Mesoblast Heart Failure Cell Therapy Receives Orphan Drug Designation From FDA for Prevention of Gastrointestinal Bleeding in Patients With Left Ventricular Assist Devices 6.8%

1/1 Mesoblast Submits Clinical Efficacy and Safety Data to FDA in Rolling Biologics License Application for Remestemcel-l [Yahoo! Finance News] 6.2%

Top News Decliners

4/27 Mesoblast limited (NASDAQ: MESO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock. -18.4%

6/26 Mesoblast limited (NASDAQ: MESO) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -8.9%

2/24 Consistent Outcomes Using Ryoncil™ as First-Line Treatment or Salvage Therapy in 309 Children With Steroid-Refractory Acute GVHD -8.5%

9/18 Mesoblast limited (NASDAQ: MESO) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -8.3%

4/30 Phase 2/3 Randomized Controlled Trial of Remestemcel-L in 300 Patients With COVID-19 Acute Respiratory Distress Syndrome Begins Enrollment -5.1%

5/30 Mesoblast Reports Financial Results and Operational Highlights for the Period Ended March 31, 2019 -5.0%

8/14 Remestemcel-L to be Evaluated as Treatment for Chronic Graft Versus Host Disease in Planned Investigator-Initiated Trial -4.7%

4/10 Mesoblast limited (NASDAQ: MESO) had its "buy" rating re-affirmed by analysts at HC Wainwright. -4.5%

4/1 FDA ACCEPTS MESOBLAST’S BIOLOGICS LICENCE APPLICATION FOR RYONCIL™ AND AGREES TO PRIORITY REVIEW -4.2%

10/19 Mesoblast limited (NASDAQ: MESO) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -4.2%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day